CD95
- Known as:
- CD95
- Catalog number:
- 6L95
- Product Quantity:
- 1mg
- Category:
- -
- Supplier:
- Hytest
- Gene target:
- CD95
Related genes to: CD95
- Gene:
- FAS NIH gene
- Name:
- Fas cell surface death receptor
- Previous symbol:
- FAS1, APT1, TNFRSF6
- Synonyms:
- CD95, APO-1
- Chromosome:
- 10q23.31
- Locus Type:
- gene with protein product
- Date approved:
- 1992-06-25
- Date modifiied:
- 2019-04-23
Related products to: CD95
Related articles to: CD95
- The purpose of this systematic review is to evaluate the clinical outcomes, complication rates, and failure rates following platelet-rich plasma (PRP) injections for lateral ankle ligament injuries. - Source: PubMed
Publication date: 2026/06/23
Rubin JaredRutherford RyanTham AlexanderButler James JMojica Edward SPow CameronAli Lakadawala HaiderKennedy John G - BackgroundFew studies have investigated return to play after surgical stabilization of syndesmotic injuries without fracture with minimal data on patient-reported outcome measures. The purpose of this study was to evaluate patient-reported outcomes, patient satisfaction, and return to play after surgical repair of syndesmosis injuries in competitive athletes.MethodsA retrospective review of competitive athletes who underwent surgery for an unstable syndesmosis was performed. Patients were excluded if they were not competitive athletes or had the presence of a concomitant fracture. Patient-reported outcome measures were collected via telephone questionnaires. These included the Foot and Ankle Ability Measure (FAAM) Sports Subscale as well as 7 other questions regarding subjective assessment of function, patient satisfaction, and return to play.ResultsA total of 29 ankles in 28 competitive athletes were included. Twenty-four of 28 (86%) patients were male, and 4 of 28 (14%) patients were female. Average age at surgery was 20.7 ± 2.4 (15-24). Twenty-five of 28 (89.3%) athletes completed the post-operative telephone questionnaire with a mean follow-up of 41 months (minimum 9 months). In total, 100% of patients returned to athletic activity. Nineteen of 20 patients (95%) eligible to do so returned to competition, with 16 of 25 (64%) patients reporting a return to pre-injury level of function. The average FAAM-sports score was 29.6 (max 32) ± 3.5. Twenty-four of 25 patients reported post-operative function as normal or nearly normal. Twenty-four of 25 patients reported that they were either very satisfied or satisfied. Patient-reported time of return to unrestricted play was 19.9 ± 9.8 weeks. Injury grade, repair technique, acuity of injury, and concomitant injuries were not associated with prolonged return to play or decreased FAAM scores.ConclusionA high percentage of competitive athletes undergoing surgical treatment of syndesmosis injury were able to return to their previous level of competition, with nearly all achieving good-to-excellent outcome scores and satisfaction. Severity of injury, concomitant injury, or repair technique was not found to have an effect on outcomes.Level of EvidenceIV, single-arm retrospective case series. - Source: PubMed
Publication date: 2026/06/23
Ruland Jeffrey RMercante Margaret GNovicoff Wendy MCooper M TruittPark Joseph S - Naviculocuneiform (NC) arthrodesis is indicated for multiple pathologies, including degenerative and traumatic arthritis, progressive collapsing foot deformity, and medial column instability. Despite its broad application, no consensus exists regarding the optimal fixation construct. Shape-memory dynamic compression staples offer potential advantages in midfoot fusion compared to static fixation. - Source: PubMed
Publication date: 2026/06/23
Cooperman Steven RChristie Lauren MLangan Travis MBull Patrick EPrissel Mark A - Autoimmune lymphoproliferative syndrome-like (ALPS-like) disorders are inherited conditions caused by non-FAS pathway mutations that clinically mimic ALPS, presenting with lymphoproliferation, autoimmunity, and cytopenias. This study describes a patient with STAT3-related ALPS-like disease that was initially misdiagnosed as ALPS and compares his clinical, immunological, and molecular features with those of previously reported cases to highlight diagnostic distinctions from classical ALPS. - Source: PubMed
Publication date: 2026/06/22
Mohammadi AylarHamidi Esfahani ZahraAbolhassani HassanSharafian SaminHaghi SabahatRezaei NimaYazdani RezaTavakol Marzieh - In the development of radiopharmaceuticals, high tumor accumulation is required for their diagnostic and therapeutic effectiveness. A key strategy to enhance such tumor accumulation is the incorporation of small-molecule albumin binders (ALBs) into radioligands, extending the blood circulation time through albumin interaction for efficient delivery to tumors. In this study, we systematically investigated the potential use of fatty acids (FAs) with various carbon-chain lengths (C12, C14, C16, and C18) as ALBs (FA12, FA14, FA16, and FA18). First, we synthesized four radiolabeled compounds composed of a macrocyclic radiometal chelator and various FAs ([In]In-DFA12, [In]In-DFA14, [In]In-DFA16, and [In]In-DFA18). albumin-binding assays and biodistribution studies using normal mice revealed a chain-length dependence: longer carbon chains led to higher albumin affinity and prolonged blood retention, with [In]In-DFA18 exhibiting the most favorable pharmacokinetic profile. Based on these results, we developed [In]In-PDFA18, a prostate-specific membrane antigen (PSMA)-targeted radioligand conjugated with FA18. Tumor accumulation of [In]In-PDFA18 at 24 and 96 h postinjection (p.i.) (43.70 and 52.59% injected dose (ID)/g, respectively) was markedly higher and more prolonged compared with that of the non-FA18-conjugated control radioligand, [In]In-PSMA-617 (14.86 and 5.36% ID/g). These findings suggest that FA18 is a promising ALB to improve the tumor accumulation of radioligands. - Source: PubMed
Publication date: 2026/06/23
Nakashima KazumaTanaka MaoKazuta NobukiTsuchihashi ShoheiWatanabe HiroyukiOno Masahiro